Guidance Archives - Page 92 of 637

1 minute read

Vulcan Sees FY24 Adjusted EBITDA Of $2.15B-$2.30B

February 16, 8:14 AM

Management expectations for 2024 include: Continued improvement in Aggregates segment cash gross profit per ton ($9.46 in 2023) Total shipments flat to down 4 percent (234.3 million tons in

VMC

1 minute read

Portland General Electric 2024 Guidance: Expects Adjusted EPS Of $2.98-$3.18 Vs. $3.08 Est.; Sees Cash From Operations Of $700M-$800M

By Benzinga Newsdesk

February 16, 6:09 AM

2024 Earnings Guidance PGE is initiating full-year 2024 adjusted earnings guidance of $2.98 to $3.18 per diluted share based on the following assumptions: Exclusion of the impacts of the January 2024 winter

POR

1 minute read

Bloom Energy Stock Tanks On Q4 Performance: Earnings Miss, Subpar Outlook and More

By Erica Kollmann

February 15, 6:09 PM

Bloom Energy reported quarterly earnings of 7 cents per share which missed the analyst consensus estimate of 11 cents by 36.36%. The company reported quarterly sales of $356.92 million which missed the analyst consensus estimate of $476.28 million by 25.06% and is a 22.84% decrease over sales of $462.58 million the same period last year.

1 minute read

Agile Therapeutics Announces Extension Granted By Nasdaq Hearings Panel To Regain Compliance Until March 25, 2024; Sees FY23 Revenue $20M-$21M

By Benzinga Newsdesk

February 15, 5:55 PM

Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of

AGRX

1 minute read

Toast Stock Pops After Hours On Q4 Performance – Here’s Why

By Erica Kollmann

February 15, 5:54 PM

Toast reported quarterly losses of 7 cents per share which beat the analyst consensus estimate of losses of 11 cents per share by 36.36%. The company reported quarterly sales of $1.04 billion which beat the analyst consensus estimate of $1.02 billion by 1.91% and represents a 34.72% increase over sales of $769 million from the same period last year.

TOST

7 minute read

Inventiva Reports Preliminary 2023 Fiscal Year Financial Information And Provides An Update On Its Clinical Trial NATiV3; FY23 Revenues Of €17.5 Million

By Benzinga Newsdesk

February 15, 5:49 PM

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit at €9.0 million3 as of

IVA

2 minute read

Coinbase Q4 Earnings: Revenue Beat, Surprise Profit, Crypto Update And More

By Adam Eckert

February 15, 5:48 PM

Coinbase Global Inc (NASDAQ:COIN) reported fourth-quarter financial results Thursday after the market close.

BTC

2 minute read

Northern Oil And Gas Sees Full Year 2024 Production Expected Between 115,000 – 120,000 boe Per Day, With Oil Production Estimated At 70,000 – 73,000 bbl Per Day

By Benzinga Newsdesk

February 15, 5:44 PM

PRELIMINARY 2024 PRODUCTION AND CAPITAL EXPENDITURE GUIDANCEThe Company will provide detailed line-item 2024 guidance with year-end 2023 results but is providing preliminary production and spending guidance for 2024 as

NOG

4 minute read

NOG Provides Q4 2023 Operations Update And Preliminary 2024 Guidance; Expects Q1 2024 Production Volumes To Be Slightly Lower Than Q4 Of 2023; Sees 20% YoY Growth In Production

By Benzinga Newsdesk

February 15, 5:44 PM

Company Sees 20% Year over Year Growth in ProductionNorthern Oil and Gas, Inc. (NYSE:NOG) (the "Company" or "NOG") today announced a fourth quarter 2023 operations update, also highlighting elective Ground Game

NOG

5 minute read

Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023

By Benzinga Newsdesk

February 15, 5:40 PM

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in

PRLD